Logo image of RERE

ATRENEW INC (RERE) Stock Fundamental Analysis

NYSE:RERE - New York Stock Exchange, Inc. - US00138L1089 - ADR - Currency: USD

2.91  +0.01 (+0.34%)

After market: 2.91 0 (0%)

Fundamental Rating

4

RERE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 120 industry peers in the Specialty Retail industry. RERE has a great financial health rating, but its profitability evaluates not so good. RERE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RERE had negative earnings in the past year.
In the past 5 years RERE always reported negative net income.
RERE had negative operating cash flow in 4 of the past 5 years.
RERE Yearly Net Income VS EBIT VS OCF VS FCFRERE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -1B -2B

1.2 Ratios

RERE has a Return On Assets of -2.84%. This is in the lower half of the industry: RERE underperforms 63.25% of its industry peers.
The Return On Equity of RERE (-4.21%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -2.84%
ROE -4.21%
ROIC N/A
ROA(3y)-23.13%
ROA(5y)-27.29%
ROE(3y)-29.48%
ROE(5y)-36.06%
ROIC(3y)N/A
ROIC(5y)N/A
RERE Yearly ROA, ROE, ROICRERE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 11.59%, RERE is doing worse than 91.45% of the companies in the same industry.
RERE's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RERE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.06%
GM growth 5Y28.93%
RERE Yearly Profit, Operating, Gross MarginsRERE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30 -40

More info and screens

7

2. Health

2.1 Basic Checks

RERE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RERE has less shares outstanding
Compared to 5 years ago, RERE has more shares outstanding
RERE has a worse debt/assets ratio than last year.
RERE Yearly Shares OutstandingRERE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
RERE Yearly Total Debt VS Total AssetsRERE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

RERE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC8.75%
RERE Yearly LT Debt VS Equity VS FCFRERE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 2.68 indicates that RERE has no problem at all paying its short term obligations.
RERE has a better Current ratio (2.68) than 89.74% of its industry peers.
RERE has a Quick Ratio of 2.07. This indicates that RERE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.07, RERE belongs to the top of the industry, outperforming 89.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.07
RERE Yearly Current Assets VS Current LiabilitesRERE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B

More info and screens

6

3. Growth

3.1 Past

RERE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.67%, which is quite impressive.
The Revenue has grown by 31.37% in the past year. This is a very strong growth!
The Revenue has been growing by 31.79% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
Revenue 1Y (TTM)31.37%
Revenue growth 3Y38.71%
Revenue growth 5Y31.79%
Sales Q2Q%29.93%

3.2 Future

Based on estimates for the next years, RERE will show a very negative growth in Earnings Per Share. The EPS will decrease by -34.53% on average per year.
RERE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.56% yearly.
EPS Next Y-76.62%
EPS Next 2Y-34.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.07%
Revenue Next 2Y24.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RERE Yearly Revenue VS EstimatesRERE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B
RERE Yearly EPS VS EstimatesRERE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RERE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 115.05, which means the current valuation is very expensive for RERE.
66.67% of the companies in the same industry are cheaper than RERE, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.68. RERE is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 115.05
RERE Price Earnings VS Forward Price EarningsRERE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RERE Per share dataRERE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

RERE's earnings are expected to decrease with -34.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.53%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RERE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATRENEW INC

NYSE:RERE (2/21/2025, 8:04:01 PM)

After market: 2.91 0 (0%)

2.91

+0.01 (+0.34%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)11-20 2024-11-20/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners26.37%
Inst Owner Change35.85%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap645.15M
Analysts85.71
Price Target3.21 (10.31%)
Short Float %0.14%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-89.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 115.05
P/S 0.36
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)0.03
Fwd EY0.87%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.06
BVpS2.31
TBVpS2.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.84%
ROE -4.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 11.59%
FCFM N/A
ROA(3y)-23.13%
ROA(5y)-27.29%
ROE(3y)-29.48%
ROE(5y)-36.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.06%
GM growth 5Y28.93%
F-ScoreN/A
Asset Turnover2.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.07
Altman-Z N/A
F-ScoreN/A
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100.13%
EPS Next Y-76.62%
EPS Next 2Y-34.53%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)31.37%
Revenue growth 3Y38.71%
Revenue growth 5Y31.79%
Sales Q2Q%29.93%
Revenue Next Year24.07%
Revenue Next 2Y24.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y78.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.65%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A